Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Katie Gavyert"'
Autor:
Andrea Sboner, Samaneh Motanagh, Megan Kearney, David S. Rickman, David M. Nanus, Yuzhuo Wang, Himisha Beltran, Loredana Puca, Kumiko Isse, Judy Hess, Adam J. Donoghue, Michael Sigouros, Juan Miguel Mosquera, Verena Sailer, Scott T. Tagawa, Etienne Dardenne, Katie Gavyert, Laura Saunders, Olivier Elemento, Ryan Dittamore, Heng Pan, Luisa Fernandez, Aram Vosoughi, Vincenza Conteduca
Publikováno v:
Università degli studi di Foggia-IRIS
Histologic transformation to small cell neuroendocrine prostate cancer occurs in a subset of patients with advanced prostate cancer as a mechanism of treatment resistance. Rovalpituzumab tesirine (SC16LD6.5) is an antibody-drug conjugate that targets
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fc8c414d55fd5d1b095ffe2dba7a20f
https://pubmed.ncbi.nlm.nih.gov/31040438
https://pubmed.ncbi.nlm.nih.gov/31040438
Autor:
Etienne Dardenne, David M. Nanus, Michael Sigouros, Laura Saunders, Himisha Beltran, Loredana Puca, Verena Sailor, Kumiko Isse, Juan Miguel Mosquera, Katie Gavyert, Scott T. Tagawa
Publikováno v:
Cancer Research. 78:1947-1947
Background: Delta-like protein 3 (DLL3) is expressed on the surface of small cell lung cancer (SCLC) tumor-initiating cells, and the DLL3 targeted antibody-drug conjugate, Rovalpituzumab tesirine (Rova-T™; SC16LD6.5), has shown promise for patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4575ef609856df7231a8006027a53da2
https://doi.org/10.1158/1538-7445.am2018-1947
https://doi.org/10.1158/1538-7445.am2018-1947